Skip to main content
Log in

Toxicity and Pharmacokinetics of Sustained-Release Dexamethasone in Beagle Dogs

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

The purpose of the present study was to examine the potential ocular and systemic toxicity and toxicokinetics/pharmacokinetics of sustained-release dexamethasone in canines.

Methods

In this non-randomized study, intracanalicular depots (dexamethasone-loaded or placebo vehicle) were inserted into both eyes of 33 beagles. Tear fluid and plasma were collected for toxicokinetic/pharmacokinetic analysis of dexamethasone, ophthalmic examinations were performed for signs of toxicity, and urine and blood samples were collected for urinalysis, hematology, clinical chemistry, and coagulation analysis. Animals were observed daily for signs of toxicity. Macroscopic and microscopic evaluations were performed.

Results

Mean dexamethasone tear fluid concentration from the dexamethasone group decreased from 4245 ng/mL 6-h post-insertion to 1044 ng/mL on Day 35. All plasma dexamethasone levels were below the limit of quantitation. No systemic or ocular toxicities were attributed to the dexamethasone depot.

Conclusion

Sustained-release dexamethasone produced no identifiable ocular or systemic toxicity in this animal model, and pharmacokinetics demonstrated a tapered, sustained drug release.

Funding

Ocular Therapeutix.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–97.

    Article  CAS  PubMed  Google Scholar 

  2. Vanelli M, Pedan A, Liu N, Hoar J, Messier D, Kiarsis K. The role of patient inexperience in medication discontinuation: a retrospective analysis of medication nonpersistence in seven chronic illnesses. Clin Ther. 2009;31:2628–52.

    Article  PubMed  Google Scholar 

  3. Kholdebarin R, Campbell RJ, Jin YP, Buys YM. Multicenter study of compliance and drop administration in glaucoma. Can J Ophthalmol. 2008;43:454–61.

    Article  PubMed  Google Scholar 

  4. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–310.

    Article  CAS  PubMed  Google Scholar 

  5. Maxidex [package insert]. Fort Worth, TX: Alcon Laboratories, Inc.; 2007.

  6. An JA, Kasner O, Samek DA. Evaluation of eyedrop administration by inexperienced patients after cataract surgery. J Cataract Refract Surg. 2014;40:1857–61.

    Article  PubMed  Google Scholar 

  7. Yellepeddi VK, Sheshala R, McMillan H, Gujral C, Jones D, Raghu Raj Singh T. Punctal plug: a medical device to treat dry eye syndrome and for sustained drug delivery to the eye. Drug Discov Today. 2015;20:884–9.

    Article  CAS  PubMed  Google Scholar 

  8. Osbun JW, Ellenbogen RG, Chesnut RM, Chin LS, Connolly PJ, Cosgrove GR, et al. A multicenter, single-blind, prospective randomized trial to evaluate the safety of a polyethylene glycol hydrogel (Duraseal Dural Sealant System) as a dural sealant in cranial surgery. World Neurosurg. 2012;78:498–504.

    Article  PubMed  Google Scholar 

  9. Cosgrove GR, Delashaw JB, Grotenhuis JA, Tew JM, Van Loveren H, Spetzler RF, et al. Safety and efficacy of a novel polyethylene glycol hydrogel sealant for watertight dural repair. J Neurosurg. 2007;106:52–8.

    Article  CAS  PubMed  Google Scholar 

  10. Takach S, McGrath M, Blizzard C, et al. Influence of storage temperature on sustained release dexamethasone pharmacokinetics in a beagle model. ARVO 2015. Abstract 237-C0092.

  11. Edelman JL. Differentiating intraocular glucocorticoids. Ophthalmologica. 2010;224(Suppl 1):25–30.

    Article  CAS  PubMed  Google Scholar 

  12. Renfro L, Snow JS. Ocular effects of topical and systemic steroids. Dermatol Clin. 1992;10:505–12.

    CAS  PubMed  Google Scholar 

  13. Dexamethasone sodium phosphate [package insert]. Tampa, FL: Bausch & Lomb Incorporated; 2013.

Download references

Acknowledgments

Sponsorship and article processing charges for this study were funded by Ocular Therapeutix, Bedford, MA. Editorial assistance in the preparation of this manuscript was provided by Jennifer Klem, Ph.D., of Klem Medical Communications, LLC. Support for this assistance was funded by Ocular Therapeutix, Bedford, MA. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published.

Disclosures

Arthur Driscoll is an employee and equity holder of Ocular Therapeutix. Charles Blizzard is an employee and equity holder of Ocular Therapeutix.

Compliance with Ethics Guidelines

All institutional and national guidelines for the care and use of laboratory animals were followed.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Arthur Driscoll.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 293 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Driscoll, A., Blizzard, C. Toxicity and Pharmacokinetics of Sustained-Release Dexamethasone in Beagle Dogs. Adv Ther 33, 58–67 (2016). https://doi.org/10.1007/s12325-015-0280-7

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-015-0280-7

Keywords

Navigation